The CSL Ltd (ASX: CSL) share price is in the green today after the company presented at the 2022 Macquarie Australia Conference in Sydney.
CSL shares are currently swapping hands at $275.38, a 1.82% gain. In contrast, the S&P/ASX 200 Index (ASX: XJO) is 0.1% lower at the time of writing.
Let’s take a look at what CSL reported today.
CSL informed the market that plasma collections are now at roughly the same level as prior to the COVID-19 pandemic.
In a presentation at the Macquarie conference, CSL also advised the company’s gross margin is predicted to return to pre-COVID levels in the future. CSL is working on technology improvements to plasma collection, reducing donation time by 30%.
CSL reported capital expenditure (CAPEX) is expected to be about $1.2 billion in FY22.
The company also highlighted the benefits of the Vifor Pharma acquisition. CSL is expecting regulatory approvals and closure on this deal by mid-2022.
CSL conducted a $750 million share plan for the acquisition in February, receiving strong support.
The CSL share price climbed nearly 2% in April amid multiple positive broker notes. Citi has placed a $335 price target on the company’s share price. This is nearly a 22% upside on the current share price.
The CSL share price has climbed 1.55% in the past year but it has fallen more than 5% year to date.
For perspective, the benchmark S&P/ASX 200 Index (ASX: XJO) has returned nearly 5% over the past year.
CSL has a market capitalisation of about $132.6 billion based on today’s share price.
Source: Read More